As of June 13, 2025, Cardiff Oncology Inc (CRDF) reports a Gross Margin of 100.00%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Cardiff Oncology Inc's Gross Margin
Over recent years, Cardiff Oncology Inc's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2022-12-31 | -57.89% |
| 2021-12-31 | -254.90% |
| 2020-12-31 | -355.26% |
This steady improvement highlights how Cardiff Oncology Inc manages its operational efficiency and pricing power over time.
Comparing Cardiff Oncology Inc's Gross Margin to Peers
To better understand Cardiff Oncology Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Cardiff Oncology Inc (CRDF) | 100.00% |
| Immunic Inc (IMUX) | 7775.20% |
| Kezar Life Sciences Inc (KZR) | 7775.20% |
| Vistagen Therapeutics Inc (VTGN) | 7775.20% |
| Sensei Biotherapeutics Inc (SNSE) | 7775.20% |
| Aeglea Bio Therapeutics Inc (AGLE) | 7775.20% |
Compared to its competitors, Cardiff Oncology Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.